NAD+ Decline After 40: What You Can Actually Do About It

Why does NAD+ really drop after 40 — is it a production or destruction problem?

Most NAD+ marketing frames the decline as "your body stops making enough NAD+." The more accurate framing, based on the research, is that an enzyme called CD38 starts eating it faster than your body can recycle it. Fixing only the supply side misses half the equation.

For years, the assumption was straightforward: NAD+ declines because the salvage pathway — the recycling system that rebuilds NAD+ from nicotinamide — slows down with age. The solution seemed obvious: flood the system with more precursor (NMN or NR) and let the enzymes do their work.

Then, in 2016, Camacho-Pereira and colleagues at the Mayo Clinic published a study that reframed the entire field. They showed that CD38, an ectoenzyme expressed on immune cells, is the primary driver of age-related NAD+ decline. CD38 expression and activity increase with aging, and mice engineered without CD38 maintained youthful NAD+ levels and mitochondrial function even at advanced age. The decline was not about production failing — it was about consumption accelerating (PMID 27304511).

A critical follow-up came from Tarragó et al. (2018), who tested a potent CD38 inhibitor called 78c in naturally aged mice. The results were striking: 78c reversed age-related NAD+ decline and improved glucose tolerance, muscle function, exercise capacity, and cardiac function. The improvements depended on tissue NAD+ levels and were reversed when NAD+ synthesis was blocked — confirming that the mechanism was genuinely NAD+-mediated (PMID 29719225).

Crucially, CD38 does not only consume NAD+ — it also degrades NMN itself before it can be converted to NAD+. This means that in a body with high CD38 activity (which is every aging body), some of the NMN you swallow is being destroyed before it reaches your cells. This is why the "just take more NMN" approach has a ceiling, and why addressing CD38 is the other half of the equation.

Does exercise raise NAD+ more than supplements?

Regular aerobic exercise upregulates NAMPT — the rate-limiting enzyme in NAD+ recycling — through AMPK activation. Multiple studies suggest exercise raises NAD+ more effectively than any supplement tested to date. It also reduces CD38 activity by lowering chronic inflammation.

When you exercise, the acute energy demand in muscle tissue activates AMPK (AMP-activated protein kinase), your cells' fuel gauge. AMPK responds to the energy deficit by upregulating NAMPT (nicotinamide phosphoribosyltransferase), which is the bottleneck enzyme in the NAD+ salvage pathway. More NAMPT means faster NAD+ recycling — your body converts the nicotinamide fragments back into functional NAD+ more efficiently.

Aerobic exercise is roughly 9% more effective at increasing NAMPT than resistance training alone, though both contribute. The practical target: 30–45 minutes of moderate-to-vigorous aerobic exercise, 4–5 times per week. HIIT (high-intensity interval training) creates the strongest acute AMPK signal, but consistent moderate exercise provides better sustained NAD+ support than occasional intense sessions.

Exercise also attacks the drain side: regular physical activity reduces systemic inflammation (CRP, IL-6), which lowers CD38 expression. It reduces visceral fat, another driver of chronic inflammation and CD38 upregulation. And it improves mitochondrial biogenesis independently of NAD+ — creating new mitochondria to replace the damaged ones that inefficient NAD+ cycling has accumulated.

This is why the NMN runner trial (Liao et al., 2021) — where NMN combined with exercise training produced dose-dependent aerobic improvements — showed the strongest functional result in the NMN literature (PMID 34238308). The two interventions are synergistic: exercise primes the pathway, NMN provides extra substrate.

Can NMN and NR actually refill the NAD+ tank?

Both NMN and NR reliably double circulating NAD+ in human trials within 14 days. There is no clinically meaningful difference between them for this purpose. The choice is practical — cost, availability, form — not scientific.

A 2026 head-to-head human trial (Christen et al., Nature Metabolism (PMID 41540253)) directly compared NMN, NR, and nicotinamide in 65 healthy adults. At 1,000 mg/day for 14 days, NMN and NR approximately doubled circulating NAD+. Plain nicotinamide did not sustain elevation. This settles the "which precursor" debate at the biomarker level: they are equivalent.

The 2026 systematic review by Gallagher et al. examined 33 human studies and confirmed consistent NAD+ elevation with good tolerability, but noted that downstream functional outcomes remain "heterogeneous and often null" (PMID 41655607). The practical dose range is 250–500 mg/day for general NAD+ support, with up to 1,200 mg/day tested safely in the exercise trial.

A key nuance: a 2025 post-hoc analysis found striking individual variability in NAD+ response to NMN. Some people are strong responders; others see minimal elevation at the same dose. Gut microbiome composition may explain part of this variability, since the Christen trial found that gut bacteria convert NMN and NR to nicotinic acid as an intermediate step. For the full NMN evidence picture: NMN Benefits. For precursor comparisons: NMN vs NAD.

Do CD38 inhibitors like apigenin actually preserve NAD+?

Apigenin (found in chamomile, parsley, celery) and quercetin (found in onions, apples, green tea) inhibit CD38 in preclinical models, preserving NAD+ by slowing its degradation. This is the "protection" side of the equation — complementary to NMN, not a replacement for it.

Escande et al. (2013) demonstrated that apigenin and quercetin inhibit CD38 enzymatic activity and raise intracellular NAD+ levels in cell and animal models. Apigenin was the more potent of the two, with effects on both CD38 activity and downstream sirtuin activation (PMID 23172919).

The 78c study (Tarragó et al., 2018) used a synthetic CD38 inhibitor far more potent than dietary flavonoids and achieved dramatic results in aged mice — improved glucose tolerance, muscle function, exercise capacity, and cardiac function — all NAD+-dependent. This proves the concept that blocking CD38 can reverse age-related functional decline through the NAD+ pathway (PMID 29719225).

The caveat: apigenin and quercetin are dramatically less potent than 78c. Dietary doses from food (chamomile tea, parsley, onions) provide trace amounts. Supplemental apigenin (50–100 mg) reaches higher concentrations but lacks human clinical trials for NAD+ elevation specifically. Additionally, apigenin inhibits cytochrome P450 liver enzymes, which can alter the metabolism of blood thinners, statins, and other medications. If you take prescription drugs, consult your pharmacist before adding concentrated apigenin.

The honest assessment: CD38 inhibition is the most intellectually compelling piece of the NAD+ puzzle, with the strongest preclinical support and the weakest human evidence. It is the rational complement to NMN, but it is not yet proven in people.

Does fasting help preserve NAD+ levels?

Time-restricted eating and intermittent fasting activate AMPK and SIRT1, both of which improve NAD+ cycling and mitochondrial efficiency. This is the lowest-cost, most accessible NAD+ intervention — and it requires no supplement.

Caloric restriction has been the most replicated longevity intervention in model organisms for decades, and much of its benefit traces to NAD+/sirtuin pathway activation. When energy intake drops, AMPK senses the deficit and upregulates NAMPT (the NAD+ salvage enzyme). Simultaneously, SIRT1 activation improves mitochondrial biogenesis and efficiency.

You do not need extreme caloric restriction to capture some of this benefit. Time-restricted eating (16:8 or 18:6 windows) creates a daily fasting period long enough to activate AMPK without requiring caloric counting. The fasting window matters more than the eating window — the metabolic shift toward fatty acid oxidation and AMPK activation begins roughly 12–14 hours into a fast.

Fasting also reduces senescent cell burden over time. Senescent cells secrete the SASP (senescence-associated secretory phenotype) — a cocktail of inflammatory cytokines that upregulates CD38 in neighboring cells, accelerating NAD+ depletion in a cascade. Fewer senescent cells means less SASP, less CD38 upregulation, and slower NAD+ drain.

How does chronic inflammation drive NAD+ decline?

Chronic low-grade inflammation ("inflammaging") is the upstream trigger for CD38 upregulation. Every point of CRP reduction is a point of NAD+ preserved. Anti-inflammatory diet, adequate sleep, visceral fat reduction, and stress management are not "lifestyle tips" — they are direct NAD+ interventions.

The CD38 story has an inflammation chapter. CD38 expression is driven by inflammatory cytokines, particularly those secreted by senescent cells and visceral adipose tissue. Inflammaging — the chronic, low-grade inflammatory state of aging — is not just a separate problem running in parallel with NAD+ decline. It is a direct cause of it.

This means that anything reducing systemic inflammation is also an NAD+ intervention: omega-3 fatty acids (lower IL-6 and CRP), adequate sleep (sleep deprivation raises inflammatory markers), visceral fat reduction (every kilogram of visceral fat lost reduces inflammatory cytokine output), and stress management (chronic cortisol elevation drives inflammatory gene expression).

The combined protocol that makes biological sense: exercise (raises NAMPT, lowers inflammation, reduces visceral fat) + time-restricted eating (activates AMPK, reduces senescent cells) + NMN 250–500 mg/day (provides precursor substrate) + dietary apigenin/quercetin or supplemental forms (slows CD38 drain). This hits all four mechanisms — supply, recycling, protection, and upstream inflammation — simultaneously.

What does a practical NAD+ protocol look like at 40?

The evidence-based approach layers free interventions (exercise, fasting, sleep) as the foundation, adds NMN or NR as the primary supplement, and optionally includes CD38-inhibiting compounds. Expect 8–12 weeks for any downstream effect. Track objective measures, not feelings.

Foundation (free, strongest evidence): Aerobic exercise 4–5x/week, 30–45 min. Time-restricted eating (16:8 minimum). 7–8 hours sleep in a dark, cool room. Anti-inflammatory diet emphasis (omega-3, vegetables, reduced processed food).

Primary supplement: NMN 250–500 mg/day, taken in the morning. Or NR at equivalent dose — no meaningful difference for NAD+ elevation. For the full mechanism and dosing rationale: What Is NMN?

Optional CD38 support: Apigenin 50 mg/day (from supplement) or regular chamomile tea + quercetin-rich foods (onions, apples, green tea). Note the CYP450 interaction risk with medications.

Baseline bloodwork: Before starting, check thyroid (TSH), iron (ferritin), testosterone, fasting glucose, and vitamin D. NAD+ decline does not explain fatigue caused by thyroid dysfunction, iron deficiency, or clinical testosterone deficiency. Rule those out first.

Timeline: NAD+ blood levels rise within days of NMN supplementation. Downstream mitochondrial and functional adaptation takes 6–12 weeks. Exercise-induced NAMPT upregulation is detectable within 2 weeks of regular training. Do not judge the protocol before 12 weeks.

For how NMN fits into a broader fatigue strategy that also addresses testosterone and cortisol: Low Energy Supplements for Men Over 40. For the foundational NAD+ biology: The NAD+ Energy Gap.

Is NMN enough by itself to fix NAD+ decline?

No. NMN provides the raw material, but if CD38 activity is high (which it is in every aging body with chronic inflammation), some of that NMN is degraded before conversion. The two-front approach — supply (NMN) plus protection (exercise, anti-inflammatory lifestyle, CD38 inhibitors) — is more biologically complete than either alone.

Does exercise actually raise NAD+ as much as supplements?

Some researchers argue exercise raises NAD+ more effectively than any supplement studied to date, through AMPK-mediated NAMPT upregulation. The advantage of exercise is that it simultaneously improves mitochondrial biogenesis, reduces inflammation, and lowers CD38 — hitting multiple NAD+ mechanisms at once. Supplements provide precursor substrate; exercise optimizes the entire pathway.

What about apigenin — is the evidence strong enough to supplement?

The CD38 inhibition data for apigenin is preclinical only — no human trial has tested whether apigenin supplementation raises NAD+ in people. The mechanism is well-characterized in cell and animal models (Escande et al., 2013, PubMed). If you are already taking NMN and exercising, adding apigenin at 50 mg/day is a reasonable, low-risk addition — but it is a bet on mechanism, not a proven intervention.

How do I know if my NAD+ is actually low?

Consumer-available NAD+ blood tests exist (Jinfiniti's Intracellular NAD test is the most cited), but there is no consensus on clinical reference ranges, and a single blood draw captures a snapshot that varies with time of day, recent exercise, and food intake. The practical approach is to assume age-appropriate decline (it is universal after 40) and intervene based on the population-level evidence rather than chasing a personal biomarker with uncertain clinical meaning.

What are the most common NAD+ mistakes people make after 40?

The three most common mistakes are taking NMN without exercising, expecting results in days instead of weeks, and ignoring the inflammation side of the equation entirely. A fourth — chasing NAD+ blood tests without understanding their limitations — wastes money and creates false confidence.

Mistake 1: NMN without exercise. Taking a NAD+ precursor while sedentary is like adding fuel to a car that is parked. NMN provides substrate for the salvage pathway, but exercise is what activates AMPK and upregulates NAMPT — the enzyme that actually converts the precursor into usable NAD+. The strongest functional NMN trial result (Liao et al., 2021, PMID 34238308) came in people who were training alongside supplementation. Without the exercise signal, you are supplying raw material to a factory that has not been told to increase production.

Mistake 2: Expecting acute energy. NAD+ precursors are not stimulants. They do not block adenosine (like caffeine) or spike dopamine (like pre-workouts). Blood NAD+ levels rise within days of starting NMN, but the downstream mitochondrial adaptations — more efficient electron transport, improved ATP yield per unit of food — take 6–12 weeks to manifest. If you are judging NMN by how you feel on day three, you are measuring the wrong thing on the wrong timeline.

Mistake 3: Ignoring inflammation. Chronic low-grade inflammation drives CD38 upregulation, which is the primary cause of NAD+ decline in the first place. Taking NMN while eating a processed diet, sleeping poorly, and carrying excess visceral fat is like bailing water from a boat without plugging the hole. The inflammation → CD38 → NAD+ depletion cycle will outpace your supplementation. Addressing inflammation through diet, sleep, and exercise is not optional — it is the prerequisite that makes NMN effective.

Mistake 4: Chasing NAD+ blood tests. Consumer NAD+ blood tests exist, but there is no clinical consensus on reference ranges, optimal levels, or what a specific number means for your daily function. A single blood draw captures a snapshot influenced by time of day, recent exercise, food intake, and supplement timing. The practical approach: assume age-appropriate decline (it is universal), implement the two-front protocol (supply + protect), and track functional outcomes (exercise recovery, resting heart rate, sleep quality) rather than a biomarker with uncertain clinical meaning.

Mistake 5: Neglecting the basics. NAD+ decline is real, but it is rarely the only — or even the primary — cause of fatigue in a 40-year-old. Untreated hypothyroidism, iron deficiency, low testosterone, sleep apnea, and vitamin D deficiency are all more common and more treatable than mitochondrial NAD+ shortfall. A basic blood panel (TSH, ferritin, total/free testosterone, vitamin D, fasting glucose) costs under $200 and rules out causes that no amount of NMN will fix. Do this before spending money on any NAD+ strategy.

Which NMN trials showed real physical improvements?

Three human trials found measurable physical performance gains from NMN. The strongest showed dose-dependent aerobic capacity improvement in recreational runners. Two others showed walking speed and grip strength improvements in older adults. All were small and short-term.

Aerobic capacity in runners. Liao et al. (2021) conducted a 6-week randomized, double-blind trial with 48 recreationally trained runners receiving NMN at 300, 600, or 1,200 mg/day. NMN dose-dependently improved ventilatory threshold and enhanced O2 utilization in skeletal muscle. The researchers concluded that "NMN increases the aerobic capacity of humans during exercise training, and the improvement is likely the result of enhanced O2 utilization of the skeletal muscle" (PMID 34238308). This is the strongest exercise-performance result for NMN to date — but it measured performance during training, not resting energy levels.

Gait speed and grip strength in older men. Igarashi et al. (2022) gave 42 healthy older men 250 mg NMN/day for 6–12 weeks in a placebo-controlled, double-blind trial. NMN partly improved muscle performance measured by gait speed and grip strength, though the effects were modest and not all endpoints reached significance (PMID 35927255).

Walking endurance and NAD+ elevation. A multicentre RCT by Yi et al. (2023) tested 300–900 mg/day of NMN (Uthever brand) for 60 days and found dose-dependent NAD+/NADH increases (the primary endpoint) along with improved 6-minute walking distance, though the walking improvement did not reach statistical significance in all dose groups (PMID 36482258).

The honest reading: NMN's strongest functional signal is in aerobic exercise capacity when combined with training. For the "I'm just tired at my desk" fatigue that most 40-year-olds describe, the evidence is not there yet. That does not mean it does not work — it means no one has measured it in the right population, with the right outcome, for long enough.

References

Source	Title	Journal
Escande C (2013)	Flavonoid apigenin is an inhibitor of the NAD+ase CD38	Diabetes
Gomes AP (2013)	Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging	Cell
Camacho-Pereira J (2016)	CD38 dictates age-related NAD decline and mitochondrial dysfunction	Cell Metabolism
Tarragó MG (2018)	A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction	Cell Metabolism
Liao B (2021)	NMN supplementation enhances aerobic capacity in amateur runners	J Int Soc Sports Nutr
Igarashi M (2022)	Chronic NMN supplementation elevates blood NAD+ and alters muscle function in healthy older men	npj Aging
Yi L (2023)	The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial	GeroScience
Gallagher R (2026)	NAD+ supplementation for anti-aging: PRISMA-guided systematic review	Ageing Research Reviews
Christen S (2026)	Head-to-head comparison of NMN, NR, and nicotinamide in humans	Nature Metabolism